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Abstract
Background: Human papillomavirus has been implicated in virtually all cervical cancers and is
believed to be the primary etiological factor that transforms cervical epithelia. The presence of HPV
in oral cancers suggests that HPV may play a similar role in transforming the oral epithelia. The
prevalence of HPV in oral cancers is highly variable, however, presenting problematic issues
regarding the etiology of oral cancers, which must be investigated more thoroughly. Past analyses
of HPV in cancers of the oral cavity have largely been confined to retrospective studies of cancer
patients. The purpose of this study was to examine the potential for HPV16 infection to alter the
proliferative phenotype of oral squamous cell carcinoma in vitro.
Results: This study found that the oral squamous cell carcinoma cell line, CAL27, transfected with
HPV16, exhibited significantly increased proliferation, compared with non-transfected CAL27. The
increased proliferation was observed under low density conditions, even in the absence of serum.
Moreover, these effects were specific to proliferation, adhesion, and morphology, while cell viability
was not affected.
Conclusion: This study represents one of the first investigations of the effects of HPV16 infection
on the proliferation, adhesion, and morphology of an oral squamous cell carcinoma cell line in vitro.
The finding that HPV16 has the ability to measurably alter adhesion and proliferative potential is
significant, indicating that HPV may have multiple influences on precancerous and cancerous lesions
and should be explored as a risk factor and mediator of cancer phenotypes. These measurements
and observations will be of benefit to researchers interested in elucidating the mechanisms of oral
cancer transformation and the factors governing carcinogenesis and progression.
Background
Human papillomavirus (HPV) has been implicated in
many intraepithelial neoplasias and invasive squamous
cell carcinomas [1-3]. The worldwide prevalence of HPV
in cervical carcinomas has been determined to be as high
as 99.7%, with HPV types 16 and 18 implicated most fre-
quently [4,5]. Recent studies indicate that of these two
high risk types of HPV, HPV16 is the most prevalent type
found in oral cancers, most notably in oral squamous cell
carcinomas (OSCC). These studies have also provided evi-
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dence that oral infection with HPV is a significant inde-
pendent risk factor for OSCC, determining that HPV is
detected in 46.5% of OSCC, compared with its detection
in 10% of normal oral mucosa [6-10].
Why HPV is found in virtually all cervical cancers, but
only in a subset of OSCC, has yet to be explained. The
mechanism of HPV carcinogenesis has been well estab-
lished for cervical cancers. Early studies have demon-
strated that the HPV-expressed E6 and E7 proteins
function concomitantly to disrupt the p53 and Rb tumor
suppressor genes, regulators of cell-cycle checkpoints at
the G1 phase [5,11,12]. These pathways have also been
implicated in head and neck cancers [13], suggesting the
plausible assumption that HPV may also play a similar
and significant role in the development of oral cancers.
Much of the literature related to HPV infection and oral
cancers involves epidemiologic studies and retrospective
analyses of tumor biopsies and HPV infection in OSCC.
Despite the correlative evidence of HPV infection with
oral cancer, other investigations have discovered that
HPV16 is rarely found in premalignant oral lesions, and
may therefore not be necessary for progression of oral
mucosa to malignancy [8,14,15]. The results of some
studies even suggest that patients with certain HPV posi-
tive oral cancers seem to have greater survival rates than
those with oral cancers that are negative for HPV [7,10].
While the aforementioned studies have informed our
understanding of HPV prevalence in oral cancers and have
begun to explain the mechanisms of HPV transformation,
they have not adequately addressed the apparent contra-
dictory evidence that HPV infection may not be causally
related to the formation of all, or even most, oral carcino-
mas. For instance, although some studies have demon-
strated the transformation of human foreskin and cervical
keratinocytes in vitro using HPV16 [3,16], no studies thus
far have sufficiently investigated the role of HPV in
already transformed OSCC; in particular, no in vitro stud-
ies have established or defined the role of acquired HPV
with alterations of the proliferative phenotype of OSCC.
One possible explanation for the presence of HPV DNA in
oral cancer biopsies, but not in premalignant oral lesions,
may be the inability of PCR and other detection tech-
niques to distinguish between HPV infections causally
related to cancer development and those that are concom-
itant, non-causal HPV infections [9,17]. By examining the
effects of HPV16 infection on transformed OSCC in vitro,
the etiologic factors that are necessary and sufficient to
induce transformation of the oral mucosa, and those fac-
tors that may only promote proliferative potential in
already transformed OSCC, can be elucidated.
The goal of this study was to examine the role of HPV16
infection in altering proliferative phenotype of OSCC in
vitro. We hypothesized that HPV16 infection of the OSCC
cell line, CAL27, would mediate phenotypic alterations of
these cells, particularly adhesion, proliferation, and mor-
phology. We tested this hypothesis by transfecting CAL27
with the full-length HPV16 genome and establishing cel-
lular adhesion and proliferation assays for HPV16-trans-
fected and non-transfected CAL27.
Our results provide one of the first demonstrations that
HPV16 significantly affects the proliferative potential of
CAL27  in vitro. Furthermore, HPV16 transfection pro-
duces measurable differences in adhesion and morphol-
ogy in CAL27 cells, compared with non-transfected
controls.
Results
Transfection and RT-PCR
To confirm that CAL27 does not already harbor HPV16,
we performed RT-PCR on total RNA isolated from cul-
tured CAL27 cells using oligonucleotide primers specific
for HPV16. In addition, two HPV16-negative cervical car-
cinoma cell lines, HTB-32 and GH354, were included as
controls. Our results demonstrated that CAL27, HTB-32,
and GH354 did not express HPV16 mRNA (Fig.1A: lanes
1–3). Primers specific for the γ2-subunit of the extracellu-
lar matrix (ECM) protein, laminin-5, were used as a posi-
tive control (Fig.1A: lanes 4–6).
We tested the effectiveness of the transient transfections of
CAL27 with HPV18 by performing RT-PCR on CAL27-
HPV18 and a cell line known to harbor endogenous HPV
18, GH354. The HPV18-negative cell line, HTB-32, was
included as a control. Our results demonstrated that
CAL27-HPV18 and GH354 expressed HPV18 mRNA (Fig.
1B: lanes 4–5). Our results also indicated, however, that
HTB-32 cell line, purported to be HPV negative, expressed
HPV18 mRNA (Fig. 1B: lane 3). Our results further veri-
fied the absence of HPV16-specific mRNA in these cell
lines (Fig. 1B: lanes 1, 2, 6).
We completed transient transfections of CAL27 with
HPV16 and with HPV18 subtypes. Our results indicated
that CAL27-HPV16 transfectants expressed HPV16-spe-
cific mRNA and CAL27-HPV18 transfectants expressed
HPV18-specific mRNA (Fig. 1C: lanes 3–4). Furthermore,
we demonstrated that CAL27 does not express HPV16 or
HPV18 mRNA (Fig. 1C: lanes 1–2) and that each transfec-
tion was specific for the HPV subtype (Fig. 1C: Lanes 5–6).
Densitometric measurements of RT-PCR band intensity
for comparison of endogenous HPV to transient transfec-
tions revealed a 1.25-fold higher level of HPV expression
in CAL27-HPV18 transfectants (Fig. 1D). Comparison ofCancer Cell International 2006, 6:14 http://www.cancerci.com/content/6/1/14
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HPV16 and HPV18 CAL27 transfectants from subsequent
experiments confirmed HPV18-specific mRNA expression
was approximately 1.25-fold that of endogenous HPV
mRNA expression, while HPV16-specific mRNA expres-
sion was roughly equivalent to endogenous HPV levels
(Fig. 1E).
Proliferation
To test our hypothesis that HPV infection alters the prolif-
erative potential of OSCC, we performed in vitro prolifer-
ation assays to determine the relative effects of HPV16
transfection on CAL27 cells. CAL27, CAL27 mock trans-
fectants (mTF) and CAL27 transfectants (HPV16) were
plated in media containing fetal bovine serum (FBS), as
well as in media containing no serum (NS), and their pro-
liferation was measured over three days in three separate,
independent experiments. Our results demonstrated that
CAL27-HPV16 cells proliferated at a significantly higher
rate from day 1 – day 3, increasing by more than 5-fold
over CAL27 when in FBS-containing media (n = 48, p <
0.01). Furthermore, CAL27-HPV16 cells were able to pro-
liferate, even in the absence of serum, at a rate signifi-
cantly higher than non-transfected CAL27 cells, increasing
by more than 3.5-fold from day 1 to day 3 (n = 48, p <
0.01) (Fig. 2A).
CAL27 and CAL27-mTF cells exhibited similar prolifera-
tion in the presence and absence of serum, varying only in
the degree to which the cells responded to the presence of
serum. In the presence of serum (FBS), CAL27 and CAL-
mTF cells proliferated by approximately 75% (1.75-and
1.72-fold, respectively) over three days and were statisti-
CAL27 cells expressed HPV 16 in vitro only after transfection Figure 1
CAL27 cells expressed HPV 16 in vitro only after transfection. RT-PCR from total RNA demonstrated that CAL27, 
HTB-32, and GH354 cells did not express HPV16 mRNA (A: lanes 1–3) but did express laminin-5 γ2-subunit, the positive con-
trol (A: lanes 4–6). RT-PCR confirmed transfection efficiency using HPV18-vector (B: lane 4), compared to HPV18-/HPV+ cell 
lines, HTB-32 and GH354 (B: lanes 3, 5); no cell lines expressed HPV16-specific mRNA (B: lanes 1, 2, 6). CAL27-HPV16-trans-
fectants expressed HPV16-specific mRNA (C: lane 3) but not HPV18-mRNA (C: lane 5) and CAL27-HPV18 transfectants 
expressed HPV18-specific mRNA (C: lanes 4) but not HPV16 (C: lane 6). CAL27 controls expressed neither HPV16 nor 
HPV18 mRNA (C: lanes 1, 2). Densitometry measurements of relative endpoint RT-PCR band intensities for endogenous HPV 
(GH354) were compared to HPV18 controls (D). CAL27 HPV-transfectant mRNA levels were compared with positive con-
trols (E).
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cally indistinguishable from each other (n = 48, p = .39).
In the absence of serum (NS), CAL27 and CAL27-mTF
cells increased in proliferation by approximately 40%
(1.42-and 1.41-fold, respectively) and were also statisti-
cally indistinguishable (n = 48, p = .50). CAL27 and
CAL27-mTF cells demonstrated an approximate increase
of 35% in the FBS treatment compared with the NS treat-
ment (1.75-fold increase in FBS vs. 1.4-fold increase in
NS). CAL27-HPV16 cells increased their response in the
presence of serum to a larger extent than did CAL27 non-
transfected cells. Furthermore, proliferation of CAL27-
HPV16 cells increased by 380% (3.8-fold) over three days
under FBS treatment and by 260% (2.6-fold) in NS condi-
tions. This represents a differential increase in FBS versus
NS treatment of HPV16-transfected cells of more than
120% (Fig. 2B).
When the data were analyzed by trial day (day 1, day 2,
day 3), and the differences in cellular proliferation
between NS and FBS were compared within each experi-
mental group (non-transfectants, mock transfectants,
HPV-transfectants), another pattern emerged. The mean
difference in cellular proliferation between NS and FBS for
CAL27 and CAL27-mTF was 1.3-fold; a 30% increase
under FBS conditions. This pattern remained constant on
day 2 and increased slightly on day 3 (1.75-fold increase
in FBS-versus NS-treated CAL27 cells, 1.5-fold increase in
FBS-versus NS-treated CAL27-mTF cells). The CAL27-
HPV16 cells, however, exhibited a mean difference in pro-
liferation between NS and FBS treatments of 1.5-fold on
day 1, 1.6-fold on day 2, and 2.4-fold on day 3 (Fig. 2C).
Since the rate of proliferation for non-transfected CAL27
cells was relatively low, we performed in vitro proliferation
assays to determine the relative, baseline levels of CAL27
cellular growth. Quiescent CAL27 cells were plated and
their proliferation was measured over three days. Our
results demonstrated a statistically significant increase
over three days for CAL27; approximately 75% (1.75-
fold) in the presence of serum (FBS) (n = 32, p < 0.01) and
approximately 50% (1.5-fold) in the absence of serum
(NS) (n = 32, p < 0.01). These results demonstrated that
the presence of serum increased CAL27 proliferation over
NS by approximately 1.5-fold, consistent with our previ-
ous observations of OSCC behavior for in vitro prolifera-
tion (Fig. 3) (n = 64, p < 0.01).
Adhesion
To determine if the HPV16-stimulated increase in CAL27
proliferation was correlated with an increase in adhesion,
thirty-minute in vitro adhesion assays were performed of
CAL27 and CAL27-HPV16. Our results from the standard
adhesion assay revealed that transfected CAL27-HPV16
cells did not sustain a significant increase in cellular adhe-
sion over non-transfected CAL27 cells (n = 32, p = .27)
(Fig. 4A).
To address the possibility that some adherent cells were
removed during the adhesion assay procedure, particu-
larly during plate suspension, we used a modification to
this procedure which resulted in the loss of fewer adherent
HPV 16 increased CAL27 proliferation in vitro Figure 2
HPV 16 increased CAL27 proliferation in vitro. CAL27 
cells were plated at low density (104 cells per well) and 
allowed to proliferate with 10% fetal bovine serum (FBS) or 
no serum (NS). Proliferation of CAL27 HPV16-transfected 
cells increased significantly from day 1 to day 3 under FBS or 
NS treatment (A) (n = 96, p < .01). Direct comparison of NS 
with FBS treatment, day 1 – day 3, demonstrated effect of 
HPV16 on CAL27 proliferation (B) (n = 96, p < .01). Direct 
comparison of day 1, day 2 and day 3 results under NS and 
FBS revealed HPV16 increased CAL27 proliferation 3.2-fold 
under NS treatment and 5.0-fold under FBS (C). Three sepa-
rate, independent replications of this experiment were per-
formed (n = 24 wells per trial).
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cells. Our results from the modified adhesion assay
revealed that HPV16 increased CAL27 adhesion in the
absence of serum by more than 43%. These effects on cel-
lular adhesion were more strongly pronounced in the
presence of serum, increasing adhesion of CAL27-HPV16
cells over non-transfected cells by more than 86%. The
modified adhesion assay did not involve plate suspen-
sion, but only the inevitable detachment forces resulting
from the fixation and staining procedure.
Our measurements indicated that approximately 20% of
initial cells remained at the conclusion of standard adhe-
sion assays. Furthermore, the modification of the adhe-
sion assay increased only the adhesion of CAL27-HPV16
cells; 1.4-fold in the absence of serum and 1.8-fold in the
presence of serum (n = 72, p < 0.01). In addition, approx-
imately 32% of CAL27-HPV16 cells that were lost in the
standard adhesion assay were retained in the NS modified
adhesion assay, while 47% were retained in the FBS mod-
ified adhesion assay.
To determine the specificity of this response, we measured
CAL27 adhesion to the extracellular matrix (ECM). Using
the standard adhesion assay, CAL27 adhesion to naked
plastic (NP), 1% bovine serum albumin (BSA), and
fibronectin (FN) were measured. Our results verified that
HPV 16 transfection did not affect CAL27 adhesion in vitro Figure 4
HPV 16 transfection did not affect CAL27 adhesion in 
vitro. The presence and expression of HPV 16 did not affect 
CAL27 adhesion, as measured by standard 30-minute adhe-
sion assays (A) (n = 32, p = .27). The presence and expres-
sion of HPV16 did, however, affect CAL27 adhesion in the 
modified adhesion assay, increasing adhesion by 43% in the 
absence of serum and 86% in the presence of serum in three 
separate, independent trials (n = 96, p < 0.01). The presence 
of HPV16 did not affect CAL27 adhesion in standard adhe-
sion assays on naked plastic (NP), or wells coated with 
bovine serum albumin (BSA), but did increase CAL27 adhe-
sion on fibronectin (FN) by 58% (B) (n = 24, p < 0.05).
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CAL27 cells proliferated slowly when plated at low density in  vitro Figure 3
CAL27 cells proliferated slowly when plated at low 
density in vitro. CAL27 cells plated at low density (104 cells 
per well) proliferated 1.5-fold over three days in the absence 
of serum and 1.75-fold in the presence of serum (A). FBS 
induced statistically significant increases in the proliferation 
of CAL27 cells in 96-well proliferation assays by day 3 (B) (n 
= 72, p < .01). Three separate, independent replications of 
this experiment were performed (n = 24 wells per trial).
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non-specific adhesion remained constant between CAL27
and CAL27-HPV16 cells (Fig. 4B). Intriguingly, the coat-
ing of wells in the adhesion assay with FN increased
CAL27 adhesion 1.7-fold (nearly 35% of total cells
adhered), while CAL27-HPV16 adhesion increased 2.8-
fold (nearly 56% of total cells adhered)(n = 96, p < 0.05),
demonstrating a statistically significant difference
between CAL27 and CAL27-HPV16 cells on FN (n = 16, p
< 0.05).
Viability and morphology
Based upon our in vitro observations, we hypothesized
that HPV16 has a direct effect on the proliferation and
adhesion of CAL27 cells. Because cellular adhesion to the
ECM may influence proliferation, we sought to examine
further how the effects of HPV may alter other cellular
phenotypes, both quantitatively and qualitatively. To this
end, we examined viability of CAL27, CAL27-mTF and
CAL27-HPV16 cells, estimating the number of viable cells
in each assay. Our results demonstrated that between 73
and 84% of cells were viable from each treatment category
used for the adhesion and proliferation assays, day 0
(Table 1). These small differences in viability did not rep-
resent statistically significant differences among these
treatments (n = 212, p = .48). In addition, our results
demonstrated that 97–99% of cells observed from all
treatment groups were viable on day 3, and were also not
statistically different (n = 561, p = .88).
To determine qualitative effects of HPV transfection of
CAL27 cells, we examined cultured CAL27 and CAL27-
HPV16 cells to estimate the proportion of spreading to
non-spreading cells. Our data demonstrated no signifi-
cant differences between CAL27 and CAL27-HPV16 cells
in the percent spreading in the 30-minute adhesion assay.
However, CAL27-HPV16 cell morphology was signifi-
cantly altered by day 1 of the proliferation assay compared
with CAL27 non-transfected controls (Table 2). Our
results of the NS trials demonstrated a ratio of 1:2
(spread:non-spread) for CAL27 cells, and a ratio of nearly
50:1 (spread:non-spread) for CAL27-HPV16 cells at day 1.
Our results of the FBS trials demonstrated a ratio of 3:1
(spread:non-spread) for CAL27 cells and nearly 60:1
(spread:non-spread) for CAL27-HPV16 cells.
Our data show similar trends at day 2 and day 3. At day 3,
for example, the ratio of spread to non-spread CAL27
non-transfectants remained constant at 1:2, while the
ratio for CAL27-HPV16 transfectants increased to over
300:1 in the absence of serum (NS). Similarly, our results
demonstrated that in the presence of serum (FBS), the
ratio of spread to non-spread CAL27 remained at 3:1,
while the ratio for CAL27-HPV16 cells increased to more
than 400:1 (Table 2).
The phenotypic changes described in these experiments
were observable between non-transfectant controls (Fig.
5A–E) and HPV16 transfectants (Fig. 5F–J). Although
basic differences in cell number were observed between
the treatment of cells with and without serum (Fig. 5B–C;
5D–DE), the more obvious differences in increased
spreading and absolute cell number among HPV16-trans-
fectants were evident (Fig. 5G–H; 5I–J).
Density-dependent proliferation
Our previous studies with OSCC proliferation in vitro
revealed that CAL27 cells proliferated more rapidly when
plated at higher densities (105 cells/well versus 104 cells/
well), under both FBS and NS treatments, nearly doubling
their proliferation even in the absence of serum (unpub-
lished). To contextualize our results from the current
study, we compared HPV16-transfected CAL27 cells to
our previous studies which had demonstrated that CAL27
proliferation was density-dependent (Fig. 6). Compara-
tive analysis of the data revealed that HPV16 transfection
of CAL27 significantly increased their proliferation at low
density to approximately 75% of the rates we previously
observed for the proliferation of non-transfected CAL27 at
Table 1: Trypan cell-viability assay
Cell Line Day Treatment Total # cells # viable # non-viable % viable
C A L 2 7 D a y  0 N S8 56 22 37 3
CAL27 Day 0 FBS 85 62 23 73
C A L 2 7 - m T F D a y  0 N S5 44 41 08 1
CAL27-mTF Day 0 FBS 54 44 10 81
C A L 2 7 - H P V 1 6 D a y  0 N S7 36 11 28 4
CAL27-HPV16 Day 0 FBS 73 61 12 84
C A L 2 7 D a y  2 N S 6 8 6 629 7
CAL27 Day 2 FBS 101 100 1 99
C A L 2 7 - m T F D a y  2 N S 7 6 7 429 7
CAL27-mTF Day 2 FBS 42 42 0 100
CAL27-HPV16 Day 2 NS 105 103 2 98
CAL27-HPV16 Day 2 FBS 178 176 2 99Cancer Cell International 2006, 6:14 http://www.cancerci.com/content/6/1/14
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high density. CAL27 cells plated at high density (Fig. 6,
A2) proliferated more rapidly than those plated at low
density (Fig. 6, A1) without serum (NS) by day 2. In the
presence of serum, CAL27 cells plated at high density (Fig.
6, B2) also proliferated more rapidly than at low density
(Fig. 6, B1) by day 2. Transfection of CAL27 with HPV16
increased low density proliferation (Fig. 6, A3; B3) to lev-
els that approximated high density proliferation rates
under both conditions (Fig. 6, A4-NS, B4-FBS). These data
were consistent for both FBS and NS treatments, demon-
strating an increase in proliferation of CAL27-HPV16 cells
to 75% of the high density level without serum and to
95% of the high-density level in the presence of serum
(Fig.6).
Discussion
HPV E6 and E7 genes code for proteins that are capable of
binding to, and inactivating, tumor suppressors, such as
Rb and p53 in cervical cancers [5,11,12]. Recent reports of
HPV infection in a number of oral cancers suggest that
HPV may also function in a similar way in transforming
normal oral mucosa [13]. The absence of HPV in prema-
lignant lesions, combined with the lower prevalence of
HPV in oral cancers, however, indicates that HPV may act
as a mediator of phenotypic changes in OSCC, rather than
being the etiological factor inducing initial transforma-
tion [18].
Effects of HPV 16 on cell spreading in vitro Figure 5
Effects of HPV 16 on cell spreading in vitro. CAL27 cells from adhesion and proliferation assays (A-E) and CAL27-HPV16-
transfected cells (F-J) were cultured in media containing NS-no serum (B,D,G,I) or FBS-fetal bovine serum (C,E, H, J). Cells 
were fixed with formalin and stained with crystal violet. Analysis revealed that HPV16+ cells increased in number and ratio of 
spreading under FBS treatment (H, J) and under NS treatment (G, I) to a greater extent than non-transfected cells under FBS 
(C, E) or NS treatments (B, D). No measurable differences in cell number or morphology were apparent in the 30-minute 
adhesion assays (A, F).
Table 2: Relative number and ratio of spreading cells.
Cell Line Assay Treatment Total # cells # spread % spread Ratio spread:non-
spread
CAL27 Adhesion N/A 45 0 0 N/A
CAL27-HPV16 Adhesion N/A 27 0 0 N/A
CAL27 Proliferation NS – day 1 23 7 30 1:2
CAL27-HPV16 Proliferation NS – day 1 94 92 98 46:1
CAL27 Proliferation FBS – day 1 63 47 75 3:1
CAL27-HPV16 Proliferation FBS – day 1 117 115 98 58:1
CAL27 Proliferation NS – day 3 86 31 36 1:2
CAL27-HPV16 Proliferation NS – day 3 >300 >300 100 >300:1
CAL27 Proliferation FBS – day 3 64 47 73 3:1
CAL27-HPV16 Proliferation FBS – day 3 >400 >400 100 >400:1Cancer Cell International 2006, 6:14 http://www.cancerci.com/content/6/1/14
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Consequently, we hypothesized that HPV16 infection
mediates phenotypic alterations in OSCC cells, particu-
larly proliferation, adhesion and morphology, and that
qualitative and statistically significant quantitative differ-
ences could be identified. This study employed the well-
characterized OSCC cell line, CAL27, to analyze the abil-
ity of HPV16 infection to alter these phenotypes. Notably,
this study found that HPV16 infection altered the CAL27
proliferative phenotype, dramatically increasing CAL27
cell growth in vitro. The quantitative measurements of pro-
liferation determined that HPV-infection increased prolif-
eration by more than 5-fold over non-transfected cells.
This study collected some of the first evidence that HPV16
induces these proliferative changes in tandem with effects
on cellular adhesion. We have demonstrated with a mod-
ified adhesion assay that HPV16 may alter adhesion, but
at levels not distinguishable from the standard adhesion
assay protocol. Furthermore we have provided evidence
that transformed oral epithelia transfected with HPV16
have increased adhesion to a specific ECM substrate,
fibronectin. These results concur with previous research
which detected that HPV-immortalized genital epithelial
cells and HPV-containing carcinoma cell lines expressed
higher levels of intracellular and extracellular fibronectin
[19,20]. These studies also found an upregulation of
pp125 FAK (focal adhesion kinase), a cytoplasmic protein
kinase that becomes active after cellular attachment to
specific ECM proteins, such as fibronectin [21,22].
In addition to demonstrating increased proliferation, this
study revealed that HPV16 also induced spreading of cells,
even under low density conditions. These results, when
combined with our data regarding the ECM-specific adhe-
sion of CAL27-HPV16 on fibronectin, may represent a
possible mechanism that can explain, in part, the HPV-
mediated phenotypic changes, such as cell spreading, and
the observed changes in proliferation and adhesion.
Our results are consistent with several lines of published
evidence that suggest that HPV16 induces phenotypic
changes that relate directly to progression through the cell
cycle [9,11-13,23]. Specifically, the results of our research
indicate that HPV16 may drive proliferation of CAL27,
even when the cells are at low density. These observations
may be correlated with increased ECM production, such
as fibronectin, thereby providing a substrate-specific
response that increases the proliferative potential of this
particular OSCC under certain conditions.
These results suggest that a clear understanding of the role
and contributions of infections, such as HPV, may provide
new insights into the transformation and proliferative
potential of OSCC. Further analysis of both the events
that trigger and sustain proliferation in OSCC, and the
mitigating effects of HPV infection on these existing types
of cancers, may help in the elucidation of the role of HPV
in determining the parameters of proliferative potential.
Moreover, these results do not negate the possibility that
HPV may play multiple roles in oral cancer; potentially
inducing a transformation of the normal oral mucosa in
some cases, and alternatively generating phenotypic
changes to existing OSCC, which were already trans-
formed due to other etiological factors, such as smoking
or alcohol.
Comparison of CAL27 density-dependent proliferation to  low density CAL27-HPV16 in vitro Figure 6
Comparison of CAL27 density-dependent prolifera-
tion to low density CAL27-HPV16 in vitro. CAL27 cells 
plated at high density (A:2) proliferated more rapidly than 
those plated at low density (A:1) without serum (NS) by day 
2. Cal27 cells plated at high density (B:2) also proliferated 
more rapidly than those plated at low density (B:1) with fetal 
bovine serum (FBS) by day 2. Low density proliferation of 
CAL27 (A:3; B:3) was increased by transfection with HPV16 
(A:4-NS, B:4-FBS) to levels that approximated high density 
proliferation. A,B 1,3,4 = LD (low density), A,B 2 = HD (high 
density), A,B 4 = HPV16TF (transfected).
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Conclusion
Our results demonstrate that HPV16 may be a factor that
influences the proliferative potential of OSCC in vitro.
Most notably, this study represents one of the first in vitro
analyses of the effect of HPV16 infection on the prolifera-
tive potential of transformed OSCC. The influence of
HPV16 on OSCC may allow already transformed oral
mucosa to proliferate more rapidly than OSCC which
have not been infected. Moreover, HPV16 may influence
fibronectin-specific adhesion of these cells, further pro-
moting factors that directly influence progression through
the cell cycle. Future analysis of the events that trigger and
sustain the underlying cellular mechanisms of prolifera-
tion, such as the production of, and specific adhesion to
ECM components, may aid in the design of more effective
prognostic indicators and treatments for oral cancers with
concomitant HPV infections. As more such detailed anal-
yses are conducted, the information acquired should serve
to establish a rubric for generalizing the effects that HPV
infection has on OSCC to other types of pre-existing can-
cers.
Methods
Cell culture
CAL27 (human squamous cell carcinoma), GH354
(human cervical adenocarcinoma), and HTB-32 (human
cervical carcinoma) cell lines were obtained from Ameri-
can Type Culture Collection (ATCC: Manassas, VA).
CAL27 cells were maintained in Dulbecco's Modified
Eagle's Medium (DMEM) with 4 mM L-glutamine,
adjusted to contain 3.7 g/L sodium bicarbonate and 4.5 g/
L glucose, with 1% Penicillin (10,000 units/mL)-Strepto-
mycin (10,000 μg/mL) solution and 10% fetal bovine
serum (FBS) from HyClone (Logan, UT) in 75 cm2 BD Fal-
con tissue-culture treated flasks (Bedford, MA) at 37°C
and 5% CO2 in humidified chambers. GH354 cells were
also maintained as described with the addition of 20%
FBS. HTB-32 cells were maintained in McCoy's 5A
medium with 1.5 mM L-glutamine, 2200 mg/L sodium
bicarbonate from ATCC, and 10% FBS.
Cell viability
Prior to plating cells (adhesion, proliferation assays), aliq-
uots of trypsinized cells were stained using Trypan Blue
(Sigma: St. Louis, MO) and live cells were enumerated by
counting the number of Trypan-blue negative cells using
a VWR Scientific Counting Chamber (Plainfield, NJ) and
a Zeiss Axiovert 40 inverted microscope (Gottingen, Ger-
many). At each time point (day 1–3), several wells were
processed using the Trypan stain, and live cells were enu-
merated using this procedure [24,25].
Transfection
CAL27 cells were seeded in T25 cm2 BD Falcon tissue-cul-
ture treated flasks in appropriate media as described
above and allowed to achieve 70% confluence. Cells were
then transiently transfected by adding 1 μg/mL of the full-
length human papilloma virus type 16, cloned into the
pBluescript SK-vector (ATCC #45113) or the full-length
human papilloma virus type 18, cloned into the pBR322
vector (ATCC #45152). The transfections were performed
using the Stratagene Mammalian Transfection Kit (La
Jolla, CA) according to the manufacturer's recommended
protocol for CaPO4 transfection. As part of this procedure,
CAL27 cells were co-transfected with the G418-resistant
control plasmid, pWLneo. Cells were then incubated at
37°C and 5% CO2 in humidified chambers for 24 hrs, at
which time the media was changed and the cells were
incubated as described for another 24 hrs. Cells were then
split 1:10 and incubated for 24 hrs, at which time they had
reached 30% confluence. Transfectants were then selected
using G418 antibiotic (Stratagene: La Jolla, CA), added
drop wise to the culture medium at a concentration of 100
μg/mL. After selection, CAL27-HPV16 and CAL27-HPV18
were maintained in the same cell culture conditions as
described above for CAL27. Mock transfectants of CAL27
(mTF) were also established by performing the aforemen-
tioned transfection procedures, but without using virus,
control plasmid, or G418.
RT-PCR
RNA was isolated from 1.5 × 107 cells of each of the exper-
imental and control cell lines that were cultured according
to the cell culture conditions described above, using
ABgene Total RNA Isolation Reagent (Epsom, Surrey, UK)
and the procedure recommended by the manufacture. RT-
PCR was performed with the ABgene Reverse-iT One-Step
RT-PCR Kit (ReadyMix Version) and a Mastercycler gradi-
ent thermocycler (Eppendorf: Hamburg, Germany) using
the following primers synthesized by SeqWright (Hou-
ston, TX): HPV 16 forward primer, ATGTTTCAGGAC-
CCACAGGA; HPV 16 reverse primer,
CCTCACGTCGCAGTAACTGT; laminin-5 γ2-subunit for-
ward primer, TGGTGATTACAGAAGCCAGAAGG; lam-
inin-5  γ2-subunit reverse primer,
GTCAGTTGACCTGAGCATACCCAT. One μg of template
RNA was used for each reaction. The reverse transcription
step ran for 30 min at 47°C, followed by denaturation for
2 min at 94°C. Thirty-five amplification cycles were run,
consisting of 20 sec denaturation at 94°C, 30 sec of
annealing at 58°C, and 6.5 min of extension at 72°C.
Final extension was run for 5 min at 72°C. Reaction prod-
ucts were separated by gel electrophoresis using Reliant
4% agarose gels (Cambrex: Rockland, ME). Bands were
visualized by UV illumination of ethidium-bromide-
stained gels and captured using a Kodak Gel Logic 100
Imaging System and 1D Image Analysis Software (East-
man Kodak: Rochester, NY). Quantitation of RT-PCR
band densitometry was performed using Adobe (San Jose,
CA) Photoshop imaging software, Image Analysis tools.Cancer Cell International 2006, 6:14 http://www.cancerci.com/content/6/1/14
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Proliferation assays
In vitro proliferation assays of CAL27 and CAL27-HPV16
were performed in the appropriate media that was either
supplemented with 10% fetal bovine serum (FBS) or that
contained no serum (NS) in Corning Costar 96-well assay
plates (Corning, NY). Assays were performed at two con-
centration; 1.2 × 104 cells per well (low density, LD) and
1.2 × 105 cells per well (high density, HD), and their pro-
liferation was measured over three days. Cultured cells
were fixed after 24 hrs (Day 1), after 48 hrs (Day 2), and
after 72 hrs (Day 3) using 50 μL of 10% buffered formalin,
and were subsequently stained using crystal violet 1%
aqueous solution (Fisher Scientific: Fair Lawn, NJ). The
relative absorbance was then measured at 630 nm using a
Bio-Tek ELx808 microplate reader (Winooski, VT). Data
were analyzed and graphed using Microsoft Excel (Red-
mond, WA). Three separate, independent replications of
this experiment were performed. In addition, the number
and percent of spreading and non-spreading cells were
determined by visual inspection using a Zeiss Axiovert 40
inverted microscope (Gottingen, Germany) and con-
firmed with digital image capture and Adobe Photoshop
(San Jose, CA) Image Analysis tools.
Adhesion assays
Cell adhesion assays of CAL27 and CAL27-HPV16 were
performed as previously described [26,27] in Corning
Costar 96-well assay plates (Corning, NY) at a concentra-
tion of 1.2 × 105 cells per well (100 μL of 1.2 × 106 cells/
mL solution) suspended in serum-free DMEM with no
additives. Wells were either uncoated, (NP = naked plas-
tic) or coated with 1% bovine serum albumin (BSA) in
10% non-fat dried milk solution or 20 μg/mL of fibronec-
tin solution for 1 hour (60 min.) at 25°C. Cells were then
plated and allowed to attach for 30 minutes at 37°C. For
the standard adhesion assay, non-adherent cells were
removed by suspending plates upside down in a rotating
tank of 1X PBS for 10 minutes at room temperature, 25°C.
Adherent cells were then fixed using 50 μL of 10% buff-
ered formalin and subsequently stained using crystal vio-
let 1% aqueous solution (Fisher Scientific: Fair Lawn, NJ).
For the modified adhesion assay, cells were allowed to
attach for 30 minutes at 37°C and were subsequently
fixed using 50 μL of 10% buffered formalin without the
plate suspension. The relative absorbance was then meas-
ured at 630 nm using a Bio-Tek ELx808 microplate reader.
Data were analyzed and graphed using Microsoft Excel
(Redmond, WA). Additionally, the number and percent of
spreading and non-spreading cells were determined and
confirmed in the same manner as for proliferation assays
as described above.
Statistics
The differences between treatments were measured using
a t distribution, α = .05. All samples were analyzed using
two-tailed t tests as departure from normality can make
more of a difference in a one-tailed than in a two-tailed t
test. As long as the sample size is even moderate (>20) for
each group, quite severe departures from normality make
little practical difference in the conclusions reached from
these analyses [28].
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